University Of Arizona Liver Research Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Julie A
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
NCT06546657: Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.

Completed
N/A
96
Europe
Breakfast
University of Stirling
Type 1 Diabetes
11/21
11/21
BREAK, NCT05698875: The Breakfast Rise, Education and Knowledge Study

Completed
N/A
48
Europe
High glycaemic load breakfast meal, High glycaemic load breakfast meal with additional 10g protein, Medium glycaemic load breakfast meal
University of Stirling
type1diabetes
12/23
12/23
ADOPT PGx, NCT05966129: A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)

Completed
N/A
1602
US
Pharmacogenetic testing, Clinical decisions support
Duke University, National Human Genome Research Institute (NHGRI), University of Florida, Vanderbilt University Medical Center, Indiana University School of Medicine, Icahn School of Medicine at Mount Sinai
Acute Pain
03/24
03/24
Habib, Shahid
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16

Download Options